U.S. markets open in 2 hours 59 minutes

Nabriva Therapeutics plc (NBRV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.4100-0.1900 (-7.31%)
At close: 4:00PM EST

2.3800 -0.03 (-1.24%)
Pre-Market: 6:16AM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.6000
Bid2.3800 x 1300
Ask2.4300 x 800
Day's Range2.3500 - 2.6100
52 Week Range2.3100 - 16.2000
Avg. Volume1,083,822
Market Cap50.8M
Beta (5Y Monthly)1.91
PE Ratio (TTM)N/A
EPS (TTM)-6.9050
Earnings DateNov 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • UTILITY Therapeutics Joins Antimicrobials Working Group
    PR Newswire

    UTILITY Therapeutics Joins Antimicrobials Working Group

    The Antimicrobials Working Group (AWG) announced today the addition of UTILITY therapeutics Ltd. (UTILITY) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG's membership to 13 antimicrobial drug companies.

  • The Daily Biotech Pulse: Vertex, Pfizer Earnings, Tiziana COVID-19 Vaccine Data, Decision Day For Mallinckrodt's Burn Treatment

    The Daily Biotech Pulse: Vertex, Pfizer Earnings, Tiziana COVID-19 Vaccine Data, Decision Day For Mallinckrodt's Burn Treatment

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 1) Abbott Laboratories (NYSE: ABT) Adamas Pharmaceuticals Inc (NASDAQ: ADMS) (announced FDA approval for an expanded indication for its Parkinson's drug) argenx SE – ADR (NASDAQ: ARGX) (announced decision to proceed with the enrollment into the study of subcutaneous efgartigimod in chronic inflammatory demyelinating polyneuropathy) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) (Reddit's r/WallStreetBets forum called it the most undervalued stock in the market) Cellular Biomedicine Group Inc (NASDAQ: CBMG) DarioHealth Corp (NASDAQ: DRIO) Frequency Therapeutics Inc (NASDAQ: FREQ) Fulgent Genetics Inc (NASDAQ: FLGT) G1 Therapeutics Inc (NASDAQ: GTHX) Harvard Bioscience, Inc. (NASDAQ: HBIO) Hologic, Inc. (NASDAQ: HOLX) I-Mab ADR (NASDAQ: IMAB) Laboratory Corp. of America Holdings (NYSE: LH) Maravai Lifesciences Holdings Inc (NASDAQ: MRVI) Novavax, Inc.'s (NASDAQ: NVAX) (momentum buying following late-stage coronavirus vaccine readout and reports of commencing rolling regulatory submission for the vaccine candidate in Canada) OncoSec Medical Inc (NASDAQ: ONCS) Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP) Organogenesis Holdings Inc (NASDAQ: ORGO) Qiagen NV (NYSE: QGEN) Varian Medical Systems, Inc. (NYSE: VAR) Vericel Corp (NASDAQ: VCEL) Vincerx Pharma Inc (NASDAQ: VINC) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 1) Avidity Biosciences Inc (NASDAQ: RNA) Imara Inc (NASDAQ: IMRA) Kinnate Biopharma Inc (NASDAQ: KNTE) NLS Pharmaceutics AG (NASDAQ: NLSP) (went public Friday) Virios Therapeutics LLC (NASDAQ: VIRI) Stocks In Focus Tiziana Reports Positive Clinical Data For Orally Administered COVID-19 Treatment Tiziana Life Sciences ADR Representing 2 Ord Shs (NASDAQ: TLSA) announced positive data from the exploratory clinical study in Brazil that is investigating nasally administered Foralumab, its proprietary anti-CD3 human monoclonal antibody, either alone or in combination with orally administered dexamethasone, in COVID-19 patients. In both the treatment cohorts, no grade 3 or 4 severe adverse events were observed and all treatments were well-tolerated, the company said. CT scans of lungs showed that improvement was double that shown in patients treated with Foralumab as compared to those in the control group. The stock was jumping 40.31% to $5.36 premarket Tuesday. Hologic Collaborates With Google Cloud For Enhancing Digital Diagnostic Capabilities In Cervical Cancer Screening Hologic announced a multiyear strategic collaboration with Alphabet Inc's (NASDAQ: GOOGL) (NASDAQ: GOOG) Google Cloud that will feature the integration of Google Cloud's machine learning technologies with Hologic's Genius Digital Diagnostics System to transform screening and accelerate the eradication of cervical cancer across the globe. Genius Digital Diagnostics is a digital cytology platform to combine artificial intelligence with advanced digital imaging to help identify precancerous lesions and cancer cells in women. With the Google Cloud collaboration, the system will derive even more actionable insights from cytology slides for cytotechnologists and pathologists. Google Cloud also provides a secure and reliable cloud data architecture to further extend the system's capabilities. The stock was up 3.39% to $85.70 in after-hours trading. Vertex Q4 EPS Trails Estimate Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported fourth-quarter revenue of $1.63 billion compared to $1.41 billion a year ago. The company's non-GAAP net income improved from $1.70 to $2.51, missing the consensus estimate of $2.59. For the full year 2021, the company guided to product revenue of $6.7 billion to $6.9 billion, while analysts estimate total revenue of $6.95 billion. The stock slipped 2.52% to $225.94 in after-hours trading. Immunovant Voluntarily Pauses Enrollment Into IMVT-1401 Clinical Studies Following Elevated Cholesterol Levels In Treatment Arm Immunovant Inc (NASDAQ: IMVT) announced a voluntary pause of dosing in its ongoing clinical trials for IMVT-1401. The decision follows the unearthing of a physiological signal consisting of elevated total cholesterol and LDL levels in IMVT-1401-treated patients in a Phase 2b trial in thyroid eye disease. The shares were down 58.43% to $18 premarket Tuesday. Related Link: Attention Biotech Investors: Mark Your Calendar For February PDUFA Dates Travere Reports Positive Late-Stage Data For Kidney Disease Drug Travere Therapeutics Inc (NASDAQ: TVTX) said the pivotal Phase 3 DUPLEX Study of sparsentan in focal segmental glomerulosclerosis achieved its pre-specified interim FSGS partial remission of proteinuria endpoint after 36 weeks of treatment. Sparsentan, an investigational product candidate, demonstrated a statistically significant response on FPRE compared to the active control, irbesartan, the company said. Bristol-Myers Squibb's Psoriasis Drug Aces Pivotal Late-Stage Study Bristol-Myers Squibb Co (NYSE: BMY) announced positive results from POETYK PSO-2, the second pivotal Phase 3 trial evaluating deucravacitinib, a novel, oral, selective tyrosine kinase 2 inhibitor, for the treatment of patients with moderate to severe plaque psoriasis. The stock was up 1.51% to $63.15 premarket Tuesday. Nabriva CFO Gary Sender To Retire By Mid-March Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV) announced the retirement of its chief financial officer Gary Sender, effective as of March 12. Sender has agreed to serve as a consultant for Nabriva on an ongoing basis following his retirement to ensure business continuity, the company said. View more earnings on IBB A search has been initiated to identify a new CFO, Nabriva said. The stock was up 1.14% premarket at $2.67. BioCryst Sees Follow-On Buying On r/WallStreetBets Prop BioCryst shares are finding follow-on buying, extending the rally from Monday that was triggered by Reddit investing group r/WallStreetBets' warning of a "BioWar" against short sellers betting against the stock. The stock, which jumped 39.08% to $11.85 in regular trading Monday, was gaining another 8.78% premarket to $12.89. Vyne Therapeutics Rises On Fund Buying Vyne Therapeutics Inc (NASDAQ: VYNE) shares are advancing after a Form 4 filing with the SEC showed Perceptive Advisors bought 4.22 million shares in the company at $2.37 per share. After advancing 16.16% to $2.30 in Monday's regular session, the stock added an incremental 17.39% premarket to $2.70. CoreMedix Transfers Listing of Shares to Nasdaq CorMedix Inc. (NYSE: CRMD) announced that its shares have been approved for listing on the Nasdaq. The company's shares will continue to trade under its current symbol "CRMD" on the Nasdaq beginning Tuesday. Offerings Arcutis Biotherapeutics Inc (NASDAQ: ARQT) announced the commencement of an underwritten public offering of $150 million in shares of its common stock. All of the shares in the offering are being sold by the company. The stock was down 4.44% premarket at $34. Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) priced an underwritten public offering of 9.1 million shares of its common stock at a public offering price of $11 per share. The gross proceeds of the offering to the company are expected to be $100.1 million. The stock was trading 5.84% higher premarket to $12.15. argenx SE – ADR (NASDAQ: ARGX) said it has commenced a global offering of $750 million of its equity. The global offering will comprise an offering of ordinary shares represented by ADSs in the U.S. and certain other countries outside of the European Economic Area and a simultaneous private placement of ordinary shares in the European Economic Area and the U.K. The U.S. offering and the European private placement are expected to close simultaneously. The stock edged down 0.43% to $316.02 premarket. On The Radar PDUFA Dates The FDA will decide on Mallinckrodt PLC ‘s (OTC: MNKKQ) BLA for StrataGraft, an engineered, bilayer tissue, designed to mimic natural human skin with both inner dermis-like and outer epidermis-like layers. StrataGraft is being evaluated as a treatment option for deep partial-thickness thermal burns. Clinical Readouts Gregory Glenn, Novavax's president of R&D, is scheduled to present efficacy data updates from NVX-CoV2373, the company's protein-based vaccine candidate at a New York Academy of Science event, "The Quest for a COVID-19 Vaccine." The presentation is scheduled for 4 p.m. ET. The stock was up 4.85% to $281.32 in premarket trading after jumping 21.44% to $268.30 in regular trading Monday. Earnings: BIO-TECHNE Corp (NASDAQ: TECH) (before the market open) Catalent Inc (NYSE: CTLT) (before the market open) Haemonetics Corporation (NYSE: HAE) (before the market open) Pfizer Inc. (NYSE: PFE) (Q4 Revenues Climb 11% to $11.7 billion and adjusted EPS 42 cents Vs. Consensus Estimate of $11.43 billion and 48 cents per share; Raises FY21 adjusted EPS guidance to $3.10-$3.20 Vs. Consensus Estimate of $3.19) Amgen, Inc. (NASDAQ: AMGN) (after the market close) Related Link: The Week Ahead In Biotech: Merck, Pfizer In Earnings Mix, Plus Adamas, Mallinckrodt FDA Decisions, IPOs And More See more from BenzingaClick here for options trades from BenzingaAttention Biotech Investors: Mark Your Calendar For February PDUFA DatesThe Week Ahead In Biotech: Merck, Pfizer In Earnings Mix, Plus Adamas, Mallinckrodt FDA Decisions, IPOs And More© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Nabriva Therapeutics Announces Retirement of its Chief Financial Officer

    Nabriva Therapeutics Announces Retirement of its Chief Financial Officer

    DUBLIN, Ireland and KING OF PRUSSIA, Pa., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the retirement of Gary Sender as Chief Financial Officer (CFO), effective as of March 12, 2021. Mr. Sender has agreed to serve as a consultant for Nabriva on an ongoing basis following his retirement to ensure business continuity. Mr. Sender informed Nabriva that he plans to focus on his three public company Board roles and providing financial advisory services. A search has been initiated to identify a new CFO. “We thank Gary for his numerous contributions and strategic leadership during his time at Nabriva,” said Ted Schroeder, Chief Executive Officer of Nabriva Therapeutics. “Gary has been an integral part in the transformation of Nabriva into a commercial organization. His financial and strategic experience have been significant contributors to this evolution. Gary leaves the company in the financial position to allow us to continue to execute on bringing innovative products to patients. We wish him well in his future endeavors and want to thank him for continuing in a consulting role at least through 2021 to facilitate a smooth transition to his successor.” “I have thoroughly enjoyed my almost five years with the outstanding Nabriva team and it has been a pleasure to be part of the company’s growth and milestones,” said Mr. Sender. “I believe the current worldwide pandemic is an important reminder of the need for companies like Nabriva that have established a foundation to develop and deliver essential treatments for patients with infectious diseases. I’m excited to continue to work closely with the Nabriva team in my role as an advisor.” About Nabriva Therapeutics plc Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories. Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for Nabriva Therapeutics, including but not limited to statements about Mr. Sender’s expected consultancy position with Nabriva Therapeutics, Nabriva Therapeutics’ plans to identify a successor CFO and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: Nabriva Therapeutics’ ability to successfully implement its commercialization plans for XENLETA and whether market demand for XENLETA is consistent with its expectations, Nabriva Therapeutics’ ability to build and maintain a sales force for XENLETA, the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from clinical trials, whether results of early clinical trials or studies in different disease indications will be indicative of the results of ongoing or future trials, uncertainties associated with regulatory review of clinical trials and applications for marketing approvals, the availability or commercial potential of CONTEPO for the treatment of cUTI, the ability to retain and hire key personnel, the availability of adequate additional financing on acceptable terms or at all and such other important factors as are set forth in Nabriva Therapeutics’ annual and quarterly reports and other filings on file with the SEC. In addition, the forward-looking statements included in this press release represent Nabriva Therapeutics’ views as of the date of this press release. Nabriva Therapeutics anticipates that subsequent events and developments may cause its views to change. However, while Nabriva Therapeutics may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Nabriva Therapeutics’ views as of any date subsequent to the date of this press release. CONTACTS: For InvestorsKim AndersonNabriva Therapeutics plcIR@Nabriva.com For MediaMike BeyerSam Brown Inc. mikebeyer@sambrown.com312-961-2502